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In view of the European Union regulations 1107/2009 and 528/2012, which say that basic substances in plant protection 
and biocidal products marketed in the European Union (EU) should not have an inherent capacity to cause endocrine 
disruption, an initiative was started to define scientific criteria for the identification of endocrine disruptors (EDs). The 
objectives of the EU strategy on EDs are to protect human health and the environment, to assure the functioning of the 
market, and to provide clear and coherent criteria for the identification of EDs that could have broad application in the 
EU legislation. Policy issues were to be addressed by the Ad-hoc group of Commission Services, EU Agencies and Member 
States established in 2010, whereas the scientific issues were to be addressed by the Endocrine Disruptors Expert Advisory 
Group (ED EAG), established in 2011. The ED EAG adopted the 2002 World Health Organization (WHO) definition of 
endocrine disruptor and agreed that for its identification it is necessary to produce convincing evidence of a biologically 
plausible causal link between an adverse effect and endocrine disrupting mode of action. In 2014, the European Commission 
proposed four ED identification criteria options and three regulatory options, which are now being assessed for socio-
economic, environmental, and health impact. Slovenia supports the establishing of identification criteria and favours 
option 4, according to which ED identification should be based on the WHO definition with the addition of potency as 
an element of hazard characterisation. As for regulatory options, Slovenia favours the risk-based rather than hazard-based 
regulation.
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In 1998, the European Parliament adopted a resolution 
calling upon the European Commission (EC) to improve 
the regulatory framework for endocrine disruptors and to 
reinforce related research and communication to the public. 
In 1999, the EC proposed activities needed to respond to 
the public concern, which were based on the precautionary 
principle. It also proposed a research framework that would 
elucidate the causes and effects of identified endocrine 
disturbances. A number of research projects had been 
carried out since, and the EC had regularly reported on the 
developments in terms of substances prioritised for further 
investigation, new test methods, legislation, and further 
research (1).
Endocrine disruptors and the EU regulations
According to the widely accepted 2002 World Health 
Organization (WHO) definition,
An endocrine disruptor is an exogenous substance or 
mixture that alters function(s) of the endocrine system and 
consequently causes adverse health effects in an intact 
organism, or its progeny, or (sub)populations. A potential 
endocrine disruptor is an exogenous substance or mixture 
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that possesses properties that might be expected to lead to 
adverse health effects in an intact organism, or its progeny, 
or (sub)populations (2).
The Glossary of Terms in the IPCS Environmental 
Health Criteria no. 240 define adverse effects as follows:
An adverse effect is a change in the morphology, growth, 
development, reproduction, or lifespan of an organism, 
system, or (sub)population that results in an impairment of 
functional capacity, an impairment of the capacity to 
compensate for additional stress, or an increase in 
susceptibility to other influences (3).
EC regulations 1107/2009 (4) and 528/2012 (5) stipulate 
that basic substances, safeners, and synergists in plant 
protection products and basic substances in biocidal 
products, respectively, should not have endocrine-disrupting 
properties that may cause adverse effects if they are to be 
approved for marketing in the EU. The exceptions for plant 
protection products are if the exposure of non-target 
organisms is negligible or the “substance is necessary to 
control a serious danger to plant health which cannot be 
contained by other available means including non-chemical 
method” (4). Similarly, the exceptions for the biocidal 
products are if the risks are negligible or the substance is 
“essential to prevent or control a serious danger to human 
health, animal health or the environment or not approving 
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the substance would have “disproportionate negative 
impacts for society when compared with the risks…” (5).
However, neither regulation defines the criteria for the 
identification of ED. Until such criteria are adopted, the 
implementation of the regulations 1107/2009 and 528/2012 
relies on the provisions of the classification, labelling and 
packaging regulation no. 1272/2008 (6) in the sense that 
substances classified as carcinogenic category 2 and toxic 
for reproduction category 2 in that regulation “shall be 
considered to have endocrine disrupting properties. In 
addition, substances, such as those classified, as toxic for 
reproduction category 2 and which have toxic effects on 
the endocrine organs, may be considered to have endocrine 
disrupting properties” (4). This interim approach, of course, 
is imprecise, as carcinogenicity, reproductive toxicity, or 
even endocrine organ toxicity may have little to do with 
endocrine disruption.
Many other EU regulations are in dire need for clear 
criteria for identifying EDs (1907/2006, 1223/2009, 93/42/
EEC, 2007/47/EC, and 2000/60/EC) (7-11). Clear criteria 
will enable their universal application across the regulatory 
solutions in different settings. The initiative to further 
develop the EU strategy on EDs has the following 
objectives: to provide legally clear, predictable, and 
coherent criteria for the identification of EDs and to enable 
their universal application across the EU legislation with 
the ultimate objective of protecting human health and 
environment and of strengthening the internal EU market 
(12).
This article presents the latest developments concerning 
the efforts to come up with these universal, scientific criteria 
for the identification of EDs as well as the current position 
of the Republic of Slovenia on this issue.
Development of scientific criteria for the identification of 
endocrine disruptors
In 2010, the EC established an Ad-hoc group of 
Commission Services, EU Agencies and Member States for 
policy issues and a year later, a sub-group Endocrine 
Disruptors Expert Advisory Group (ED EAG) to address 
scientific issues relevant to endocrine disrupting substances 
not specific to any regulatory framework, including advice/
orientation on scientific criteria for the identification of 
EDs. Both groups included representatives of Commission 
services, EU agencies, member states, industry associations, 
and non-governmental organisations (NGOs).
The ED EAG was not required to reach consensus and 
presented differing opinions and options for consideration 
by the Ad-hoc group (13). It adopted the WHO definition 
of EDs (2) by analysing each of the definition’s elements. 
The starting point for discussion was the state-of-the-art 
assessment of endocrine disruptors by Kortenkamp et al. 
(14). The ED EAG agreed that the elements required for 
an endocrine disruptor to be identified were the evidence 
of an adverse effect and its relevance for humans at the 
individual and/or offspring level. To quote Kortenkamp, 
the evidence of an adverse effect requires “a biologically 
plausible causal link to an endocrine disrupting mode of 
action and for which disruption of the endocrine system 
was not a secondary consequence of other non endocrine-
mediated systemic toxicity” (14). As for the relevance, it 
should be assumed unless non-relevance can be 
demonstrated. In relation to wildlife populations, data on 
all species at the population level are generally considered 
relevant (13).
Munn and Goumenou (13) give a detailed report about 
the scientific issues raised by the ED EAG in identifying 
and characterising EDs. Briefly, potency, severity, 
irreversibility, and lead toxicity were not considered 
elements of hazard identification but characterisation. Some 
experts suggested that these elements could come in handy 
in setting priorities and ranking the EDs, and/or 
differentiating EDs into classes or categories of lower or 
higher concern based on this information, but the suggestion 
received divided support. Those who opposed it believed 
that the information could only be used within a risk 
assessment context. There was no agreement, however, on 
how to consider these factors with respect to ED hazard 
characterisation outside the context of risk assessment (13). 
Discussing a basic scheme for considering evidence of 
endocrine disrupting properties of substances, the group 
singled out mode of action and adversity and favoured the 
weight-of-evidence approach that would include human 
epidemiology data, field data, animal experimental 
toxicology and ecotoxicology studies, in vitro data, and 
quantitative structure-activity relationship. Within given 
time, the group could not fully evaluate the adequacy of 
current assays for specific endocrine pathways but 
suggested that their development “should be informed by 
emerging human health issues or observed negative impacts 
on wildlife populations and hypothesised link to endocrine-
related causes” (13). In a separate report, Munn and 
Goumenou (15) present issues, such as “effect-thresholds, 
the non-monotonous dose-response relationship, effects of 
mixtures, exposure during the critical windows of 
susceptibility, inadequacy of testing methods for the 
identification of outcomes at low doses and at the relevant 
developmental stages”.
In the meantime, the EC also gave a mandate to the 
European Food Safety Authority (EFSA) Scientific 
Committee to give their opinion on ED hazard assessment. 
The Committee proposed a distinction between an 
endocrine active substance (EAS) and ED. EAS was defined 
as “any chemical that was able to interact directly or 
indirectly with the endocrine system resulting in effect on 
the endocrine system, target organs and tissues” (16). This 
interaction, however, does not necessarily result in an 
adverse effect. In contrast, an ED should be defined by three 
criteria: an adverse effect in an intact organism or a (sub)
population; an endocrine activity; and a plausible causal 
relationship between the two. Similar to ED EAG, the 
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Committee considered critical effect, severity, (ir)
reversibility, and potency as elements of ED hazard 
characterisation (16).
Criteria for identification
In June 2014, the EC published the Roadmap of the 
initiative to define criteria for identifying EDs, in which it 
proposes four options for identification and three for 
regulatory decision making (12), as follows:
Identification options
Option 1: No policy change. No criteria are specified. 
The interim criteria set in the plant protection and biocidal 
products regulations continue to apply.
Option 2: The identification of EDs is based on the 
WHO definition. This option lists the required evidence and 
step-by-step procedure for identification.
Option 3: As option 2, but includes categories based on 
the strength of evidence for fulfilling the WHO definition: 
Category I - endocrine disruptors; Category II - suspected 
endocrine disruptors; Category III - endocrine active 
substances.
Option 4: As option 2, but includes potency as an 
element of hazard characterisation.
Decision-making options
Option A: No policy change.
Option B: Addition of more risk assessment elements 
into sectorial legislation, so that marketing decisions are 
not mainly based on hazard identification.
Option C: Inclusion of socio-economic considerations 
as well as risk-benefit analysis into sectorial legislation to 
allow marketing endocrine-disrupting products that are 
“essential to prevent adverse socio-economic impacts” (12).
The Roadmap (12) also summarises the results of the 
preliminary impact assessment for each of the options of 
the two aspects.
In the second half of 2014, a public consultation on 
defining ED identifying criteria generated over 27,000 
responses, most of which came from interest groups such 
as NGOs and farming sector rather than the general public. 
The respondents confirmed the need for the EU to establish 
definitive criteria for EDs (17). The EU strategy is due 
before the summer of 2016 (18).
Current position of Slovenia
Slovenia has actively been participating in the initiative 
to establish the ED-identifying criteria. Its current position 
is largely based on the scientific evidence presented in detail 
in the reports by Damstra et al. (2), Kortenkamp et al. (14), 
Munn and Goumenou (13, 15), EFSA (16, 19-20), EC 
Scientific Committees (21-22), Joint German-British 
position paper (23), and several other peer reviewed 
publications (24-61).
As for the identification criteria, Slovenia supports 
Option 4, which lists the required evidence and provides a 
step-by-step identification procedure, plus it includes 
potency to characterise the hazard. Potency here denotes 
relative toxicity of an agent in relation to a given or implied 
standard or reference (62); in other words, it is a measure 
of its strength in respect to other chemicals.
As for the decision-making options, Slovenia is in 
favour of Option B, which uses risk assessment as the basis 
for marketing approvals.
Concerning the effect thresholds and other uncertainties, 
the position of Slovenia is that these should be determined 
for each case separately, taking into account the weight of 
evidence for a particular chemical. Depending on the 
quantity and the quality of available data, either the 
threshold (42, 51, 54) or the non-threshold (36, 59) approach 
should be used. Slovenia also favours the use of semi-
quantitative decision trees for regulatory purposes. In view 
of uncertainties and the complexity of the endocrine system, 
Slovenia opts for a higher safety (uncertainty) factor, 
depending on the quality and quantity of data. It still remains 
to clearly define which is the sufficient quantity and 
sufficient quality of data. Considering the trends to minimise 
the use of animals in toxicological experiments and the ban 
on animal testing in cosmetics (8), it is unlikely that 
sufficient data will be generated on the effects in intact 
organisms for a number of chemicals in everyday use. For 
those structurally related to “threshold EDs”, it may be 
appropriate to reconsider using the Threshold of 
Toxicological Concern approach (63). Slovenia favours 
creating priority lists for regulation, based on potency, 
severity of effects, irreversibility, and lead toxicity, as well 
as the expected magnitude of exposure to a particular ED. 
Although these are the elements of hazard characterisation 
and risk assessment, Slovenia believes that ED regulation 
ought to be based on risk rather than hazard, provided there 
is sufficient information to assess the risk.
Instead of a conclusion
Until the identification criteria are set and EDs regulated 
across the EU legislation, we believe that it is important to 
continue raising awareness about EDs through media and 
events such as the recent conference organised by The 
Slovenian Society of Toxicology: Endocrine disrupting 
chemicals - from molecule to man (64).
In view of numerous controversies and uncertainties 
related to EDs, we believe that it is sensible to reduce 
exposure to natural and synthetic chemicals by changing 
our behaviour, regardless of current regulations. The 
following recommendations to reduce ED exposure are 
based on the national public health and chemical safety 
policies (65, 66) as well as common sense:
Maintain healthy lifestyle with balanced low-salt, low-
sugar, low-fat diet, regular moderate physical activity, and 
sufficient rest to reduce the risk of illness (and therefore the 
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need to take medication). Also avoid alcohol, tobacco, and 
caffeine.
Closely observe manufacturer’s instructions when using 
biocidal, chemical, medicinal, plant protection, and 
consumer products.
Use as few biocidal, chemical, medicinal, plant 
protection, and consumer products as possible.
Grow and prepare your own food.
Drink tap water.
Store food and water in clear glass containers and at 
appropriate temperature.
Wash hands before eating.
Minimise the number of consumer products at home 
and workplace, remove dust, and air rooms regularly.
Recycle and reuse products.
Produce as little waste as possible.
Reduce the use of electrical and electronic appliances.
Cut down on motorised travelling.
Reduce the use of cosmetics and personal hygiene 
products.
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Kemični povzročitelji hormonskih motenj - strategija Evropske unije in stališče Slovenije
Uredbi Evropske unije 1107/2009 in 528/2012 navajata, da osnovne snovi fitofarmacevtskih in biocidnih sredstev odobrene 
za uporabo v Evropski uniji (EU), same po sebi ne povzročajo hormonskih motenj. Zato je potrebno definirati znanstvene 
kriterije za identifikacijo kemičnih povzročiteljev hormonskih motenj (KPHM). Cilji strategije EU na področju KPHM 
so varovanje zdravja ljudi in okolja, zagotavljanje delovanja trga ter jasnih in skladnih kriterijev za identifikacijo KPHM, 
ki bodo omogočali široko uporabo teh kriterijev v zakonodaji. Za obravnavo politik je bila leta 2010 ustanovljena Ad-hoc 
skupina predstavnikov Evropske komisije, EU agencij in držav članic; leta 2011 pa še ekspertna svetovalna skupina (ESS), 
ki je obravnavala znanstvene vidike. ESS je privzela definicijo KPHM Svetovne zdravstvene organizacije (SZO) iz leta 
2002. Člani ESS so soglašali, da so za identifikacijo KPHM potrebni prepričljivi dokazi biološko verjetne vzročne povezave 
med škodljivim učinkom in hormonskim načinom delovanja. Evropska komisija je 2014 predlagala 4 možnosti kriterijev 
za identifikacijo KPHM in 3 možnosti obravnave. Začela se je tudi poglobljena ocena socio-ekonomskih, okoljskih in 
zdravstvenih vplivov predlaganih možnosti. Slovenija podpira uvedbo 4. možnosti, v skladu s katero kriteriji za 
identifikacijo KPHM temeljijo na definiciji SZO ob upoštevanju moči kot elementa karakterizacije nevarnosti. Slovenija 
daje prednost nadzoru, ki temelji na oceni tveganja in ne zgolj na oceni nevarnosti.
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